论文部分内容阅读
美国FDA关节炎顾问委员会一致通过,建议批准西尔公司的COX-2抑制剂celecoxib(Celebrex),用于骨关节炎(OA)和类风湿性关节炎(RA)的对症治疗。但对该药作为处理急性疼痛的附加适应证的看法不同。celecoxib在世界范围内已试用了14000余病例。期临床试验结果和安全性资料说明?..
The US FDA’s Arthritis Advisory Board unanimously approved the approval of Circe’s COX-2 inhibitor celecoxib (Celebrex) for the symptomatic treatment of osteoarthritis (OA) and rheumatoid arthritis (RA). However, the drug is treated differently as an additional indication of acute pain. celecoxib has been tested in more than 14,000 cases worldwide. Clinical trial results and safety data sheets?